Yes. As of September 2026, tirzepatide is FDA-approved as a prescription medicine in the United States. It is sold as Mounjaro for type 2 diabetes, approved in May 2022, and as Zepbound for chronic weight management, approved in November 2023. The approval covers those branded products dispensed on prescription, not research-grade tirzepatide, and the shortage-era compounding route closed in early 2025. Tirzepatide is not on WADA's 2026 Prohibited List; it is tracked under the Monitoring Program instead.
The table below shows tirzepatide's position on the five registers that decide whether a compound is approved, compoundable or prohibited in sport, and each row carries the as-of date its Peptigrity source gives.
Register | Tirzepatide's position | As of (Peptigrity source) |
|---|---|---|
FDA approval | Approved. Mounjaro for type 2 diabetes (May 2022) and Zepbound for chronic weight management (November 2023), available by prescription through licensed pharmacies. Peptigrity's regulatory snapshot lists the indication scope as obesity, type 2 diabetes and sleep apnoea. | August 2026 — tirzepatide compound page (last updated August 2026) and the regulatory snapshot (as of August 2026) |
FDA Category 2 bulk list | Not listed. Tirzepatide has never appeared on either of FDA's bulk-substances tables. Its compounding route ran through the drug-shortage list instead, and FDA declared the shortage resolved on 19 December 2024. | FDA page current 22 April 2026 — FDA regulation timeline (as of August 2026) |
PCAC review | Not assessed on Peptigrity. No Pharmacy Compounding Advisory Committee review of tirzepatide appears in the site's FDA timeline. Separately, FDA proposed on 30 April 2026 to exclude tirzepatide from the 503B bulks list, a proposal still pending as of August 2026. | Timeline covers 29 September 2023 to the 23–24 July 2026 meeting; 503B proposal as of August 2026 — compound page |
WADA | Not prohibited. Not on the WADA Prohibited List; tracked under WADA's 2026 Monitoring Program, which is not a ban. As an approved drug it sits outside the S0 catch-all for unapproved substances. | 2026 Prohibited List — compound page (last updated August 2026) and the drug-testing guide |
Other jurisdictions | EMA approval followed for both indications. Status in individual countries beyond the US and the EU is not assessed on Peptigrity. | August 2026 — compound page |
Do you need a prescription for tirzepatide?
Yes, for the approved product. Tirzepatide is a prescription medicine in the United States, available through licensed pharmacies as Mounjaro or Zepbound, and the prescription is what makes that supply lawful. Research-grade tirzepatide sold by third-party laboratories is a different supply chain: it is not the FDA-approved prescription product and carries no pharmacy-grade quality controls.
This page states what published documents say. It is legal information, not legal advice; it does not address any individual's position, and anything touching your own circumstances belongs with a qualified professional.
Can a pharmacy still compound tirzepatide?
Not as a copy of the approved product. Compounding a drug that is essentially a copy of an approved product is permitted only while that product is in shortage, so the shortage was the permission. FDA declared the tirzepatide shortage resolved on 19 December 2024, reaffirming its October 2024 determination after a court remand, and its enforcement-discretion window for compounders closed on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities. FDA's shortage database lists Tirzepatide Injection as "Resolved."
Belcourt, Sapowadia and White, writing in Annals of Pharmacotherapy and quoted in Peptigrity's regulatory snapshot, state the consequence in one sentence: "With the shortage of innovator semaglutide or tirzepatide products resolved, compounding pharmacies can only legally sell unique products." What survives is narrow and patient-specific. On 30 April 2026 FDA went further, proposing to exclude tirzepatide, along with semaglutide and liraglutide, from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them. That proposal was still pending as of August 2026; if finalised, it would close the main remaining route permanently.
Tirzepatide's absence from FDA's bulk-substances tables is not a permission. The route never ran through those tables, so checking them and finding nothing says nothing about whether compounding is open. Even the lawful compounded route carries FDA's own ceiling: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." The dated sequence is in the FDA regulation timeline for 2025–2026.
Where does research-grade tirzepatide fit?
Outside the approval entirely. The FDA approval applies to the brand owner's pharmacy-distributed prescription product, not to research-grade tirzepatide sold by third-party laboratories, which is a separate supply chain with its own quality risks: wider purity variance, occasional under-filled vials and inconsistent endotoxin control. The molecule may be the same; the product is not.
A research-use label does not change that in FDA's view. The agency "has warned companies that have illegally sold unapproved drugs... falsely labeled 'for research purposes' or 'not for human consumption.' These products have been sold directly to consumers for human use." A warning letter dated 10 December 2024 applied that reasoning to a seller of research-labelled products, holding seven of them to be unapproved new drugs because website evidence established human intended use. The enforcement in Peptigrity's record runs against sellers, and this page does not address the position of any purchaser. How the wider market behaves is covered on the grey market overview.
What does the FDA approval cover, and what does it not?
An approval is for a population and a purpose, not for a molecule. Tirzepatide's approval covers the labelled products, Mounjaro and Zepbound, for their labelled indications, prescribed by a licensed prescriber and dispensed by a licensed pharmacy. It does not extend to research-grade material, to compounded preparations, which FDA states are not FDA-approved, or to any purpose outside the label.
The approval also decides tirzepatide's position in sport. Because tirzepatide holds a marketing approval, WADA's S0 catch-all for substances with no governmental approval does not reach it, and it is not named on the 2026 Prohibited List; from 1 January 2026 its markers are monitored in and out of competition under the Monitoring Program, which tracks use without prohibiting it. Retatrutide, which holds no approval anywhere, lands on the other side of the same rule, as set out in do you need a prescription for retatrutide. Tirzepatide sits in the weight loss and metabolic category.
What does Peptigrity's lab record show for tirzepatide?
As of 21 September 2026, Peptigrity holds 1,011 independent lab tests of tirzepatide, averaging 99.74% HPLC purity (the average covers the 1,008 tests that report a purity figure), from 23 laboratories. Every result is listed on the tirzepatide lab tests page, with the compound record on the tirzepatide compound page, per-milligram prices on the tirzepatide price comparison and volume arithmetic in the tirzepatide calculator.
Read those figures for what they are. A purity percentage measures what is in a vial; it says nothing about legal status, and it cannot turn research-grade material into the approved product. The certificates are ones shops chose to publish, a selection bias Peptigrity states openly.
Frequently Asked Questions
Is tirzepatide legal in the United States?
Tirzepatide is an FDA-approved prescription medicine, so the lawful route is a prescription filled by a licensed pharmacy. Research-grade tirzepatide is not the approved product, and FDA has warned companies selling unapproved drugs labelled "for research purposes" to consumers for human use. This page states what published documents say and does not address any individual's legal position.
What is tirzepatide FDA approved for?
Type 2 diabetes, as Mounjaro, approved in May 2022, and chronic weight management, as Zepbound, approved in November 2023. Peptigrity's regulatory snapshot, as of August 2026, lists the indication scope as obesity, type 2 diabetes and sleep apnoea.
Do you need a prescription for tirzepatide?
Yes. The FDA-approved versions require a prescription and are dispensed through licensed pharmacies. A vial sold as research-grade tirzepatide is not a substitute for that route: it is not the FDA-approved prescription product and carries no pharmacy-grade quality controls.
Can you still get compounded tirzepatide?
Generally no. Mass compounding was lawful only during the shortage, which FDA declared resolved on 19 December 2024; enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities. What survives is narrow and patient-specific, and FDA's 30 April 2026 proposal to exclude tirzepatide from the 503B bulks list was still pending as of August 2026.
Is tirzepatide on FDA's Category 2 list?
No. Tirzepatide has never appeared on either of FDA's bulk-substances tables, on the page current 22 April 2026. That absence is not a permission: the compounding route ran through the drug-shortage list, and closing the shortage closed the route without any listing decision.
Is tirzepatide banned by WADA?
No. Tirzepatide is not on the WADA 2026 Prohibited List and no GLP-1 class entry exists. It is tracked under WADA's 2026 Monitoring Program, with markers monitored in and out of competition from 1 January 2026, and monitoring is not a ban.
Sources
External documents cited on Peptigrity's own pages for the statements above.
FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (2025)
FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (2026)
ZEPBOUND (tirzepatide) injection — US Prescribing Information (Drugs@FDA, 2023)
FDA — Certain bulk drug substances for use in compounding that may present significant safety risks (page current 22 April 2026)
EMJ Reviews — WADA 2026 Monitoring Program: GLP-1 receptor agonist markers tracked, not prohibited (2026, secondary report)
WADA — Prohibited List (2026)
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Tirzepatide's status row, lab record and listings live on the tirzepatide compound page. How its position compares with other compounds, axis by axis and country by country, is in are peptides legal? Regulatory status by country.